AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease [Yahoo! Finance]
AN2 Therapeutics, Inc. (ANTX)
US:NYSE Investor Relations:
ir.antheminc.com
Company Research
Source: Yahoo! Finance
biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessus M. abscessus ). The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University (OHSU), in collaboration with other investigators across an estimated 10-15 sites in the U.S. Patient screening has been initiated, with topline data planned for late 2027. Mycobacterium abscessus remains one of the most challenging pulmonary pathogens, with limited treatment options consisting of prolonged, poorly tolerated, complex, multidrug daily IV regimens," said Kevin L. Winthrop, M.D., MPH, Professor of Infectious Diseases and P
Show less
Read more
Impact Snapshot
Event Time:
ANTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANTX alerts
High impacting AN2 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ANTX
News
- AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung DiseaseBusiness Wire
- AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific HighlightsBusiness Wire
- AN2 Therapeutics raises $40M privately [Seeking Alpha]Seeking Alpha
- AN2 Therapeutics Announces $40 Million Private Placement Financing [Yahoo! Finance]Yahoo! Finance
ANTX
Earnings
- 5/13/25 - Miss
ANTX
Sec Filings
- 3/25/26 - Form D
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- ANTX's page on the SEC website